Abstract
OBJECTIVE: To provide an update on the most recent developments regarding diagnosis and outcomes of steatotic liver disease (SLD), review new nomenclature applied to SLD, and provide an approach to the diagnosis and management of SLD. SOURCES OF INFORMATION: Individual articles published mainly in the past 2 years, found using PubMed and Google Scholar. MAIN MESSAGE: Steatotic liver disease is one of the most common diseases encountered in general practice. This condition is an important biological marker for metabolic syndrome. Diagnosis relies on noninvasive tests. Known complications of metabolic syndrome and advanced liver disease are often present at the time of diagnosis. Courses of action should include assessment of cardiometabolic risk factors and progressive liver dysfunction. Subtle differences are present among patients diagnosed with SLD. Practitioners should be aware of a flux in terminology of SLD. Management of SLD can be guided using a simple algorithm. CONCLUSION: There is a need for evaluation of the SLD epidemic and its systemic nature, along with associated independent risk factors of cardiovascular disease as well as metabolic conditions such as dyslipidemia, hypertension, and type 2 diabetes.